Pediatric Advisory Committee; Amendment of Notice, 11929 [E8-4156]
Download as PDF
<![CDATA[
11929
Federal Register / Vol. 73, No. 44 / Wednesday, March 5, 2008 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Pediatric Advisory Committee;
Amendment of Notice
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug Administration
(FDA) is announcing an amendment to
the notice of meeting of the Pediatric
Advisory Committee. This meeting was
originally announced in the Federal
Register of January 25, 2008 (73 FR
4581). The amendment is being made to
reflect a change in the Agenda portion
of the document. There are no other
changes.
FOR FURTHER INFORMATION CONTACT:
˜
Carlos Pena, Office of the Commissioner
(HF–33), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–3340, e˜
mail: carlos.Pena@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
8732310001. Please call the Information
Line for up-to-date information on this
meeting.
SUPPLEMENTARY INFORMATION: In the
Federal Register of January 25, 2008,
FDA announced that a meeting of the
Pediatric Advisory Committee would be
held on March 25, 2008. On page 4581,
in the third column, the Agenda portion
of document is changed to read as
follows:
Agenda: On March 25, 2008, the
Pediatric Advisory Committee will hear
and discuss reports by the agency, as
mandated in section 17 of the Best
Pharmaceuticals for Children Act, on
adverse event reports for TOPROL XL
(metoprolol), BREVIBLOC (esmolol
HCl), LOTENSIN (benazepril), COREG
(carvedilol), COLAZAL (balsalazide),
ELOXATIN (oxaliplatin), CELEBREX
(celecoxib), and SUPRANE (desflurane).
The Pediatric Advisory Committee will
also hear an update on TRILEPTAL
(oxcarbazepine) and the FDA
Amendments Act of 2007.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/ohrms/
dockets/ac/acmenu.htm, click on the
year 2008 and scroll down to the
appropriate advisory committee link.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to the advisory committees.
Dated: February 26, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8–4156 Filed 3–4–08; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Health Resources
and Services Administration (HRSA)
publishes abstracts of information
collection requests under review by the
Office of Management and Budget
(OMB), in compliance with the
Paperwork Reduction Act of 1995 (44
U.S.C. Chapter 35). To request a copy of
the clearance requests submitted to
OMB for review, call the HRSA Reports
Clearance Office on (301) 443–1129.
The following request has been
submitted to the Office of Management
and Budget for review under the
Paperwork Reduction Act of 1995:
Proposed Project: The National Sample
Survey of Registered Nurses 2008 (OMB
No. 0915–0276)—Reinstatement With
Change
The National Sample Survey of
Registered Nurses (NSSRN) is carried
Number of
respondents
Form
jlentini on PROD1PC65 with NOTICES
Nursing Survey ........................................................................................
Written comments and
recommendations concerning the
proposed information collection should
VerDate Aug<31>2005
18:03 Mar 04, 2008
Jkt 214001
out to assist in fulfilling the
Congressional mandate of Section
806(f) of the Public Health Service Act
(42 U.S.C. 296e) which requires that
discipline-specific workforce
information and analytical activities are
carried out as part of the advanced
nursing education, workforce diversity,
and basic nursing education and
practice programs.
Government agencies, legislative
bodies and health professionals used
data from previous national sample
surveys of registered nurses to inform
workforce policies. The information
from this survey will continue to serve
policy makers, and other consumers.
The data collected in this survey will
provide information on employment
status of registered nurses (RNs), the
setting in which they are employed and
the proportion of RNs who are
employed either full-time and part-time
in nursing. The data will also indicate
the number of RNs who are employed
in jobs unrelated to nursing.
The proposed survey design for the
2008 NSSRN updates that of the
previous eight surveys. A probability
sample is selected from a sampling
frame compiled from files provided by
the State Boards of Nursing in the 50
States and the District of Columbia.
These files constitute a multiple
sampling frame of all RNs licensed in
the 50 States and the District of
Columbia. Sampling rates are set for
each State based on considerations of
statistical precision of the estimates and
the costs involved in obtaining reliable
national and State-level estimates.
Each sampled nurse will be asked to
complete a self-administered
questionnaire, which includes items on
educational background, duties,
employment status and setting,
geographic mobility, and income. An
electronic version was offered in the
2004 survey and will be again
considered as a mode for response.
Estimated burden is as follows:
Responses
per
respondent
39,984
1
be sent within 30 days of this notice to
the desk officer for HRSA, either by email to OIRA_submission@omb.eop.gov
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
Total
responses
39,984
Hours per
response
.33
Total
burden
hours
13,195
or by fax to 202–395–6974. Please direct
all correspondence to the ‘‘attention of
the desk officer for HRSA.’’
E:\FR\FM\05MRN1.SGM
05MRN1
]]>Agencies
[Federal Register Volume 73, Number 44 (Wednesday, March 5, 2008)]
[Notices]
[Page 11929]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-4156]
[[Page 11929]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Pediatric Advisory Committee; Amendment of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is announcing an amendment
to the notice of meeting of the Pediatric Advisory Committee. This
meeting was originally announced in the Federal Register of January 25,
2008 (73 FR 4581). The amendment is being made to reflect a change in
the Agenda portion of the document. There are no other changes.
FOR FURTHER INFORMATION CONTACT: Carlos Pe[ntilde]a, Office of the
Commissioner (HF-33), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-3340, e-mail:
carlos.Pe[ntilde]a@fda.hhs.gov, or FDA Advisory Committee Information
Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code
8732310001. Please call the Information Line for up-to-date information
on this meeting.
SUPPLEMENTARY INFORMATION: In the Federal Register of January 25, 2008,
FDA announced that a meeting of the Pediatric Advisory Committee would
be held on March 25, 2008. On page 4581, in the third column, the
Agenda portion of document is changed to read as follows:
Agenda: On March 25, 2008, the Pediatric Advisory Committee will
hear and discuss reports by the agency, as mandated in section 17 of
the Best Pharmaceuticals for Children Act, on adverse event reports for
TOPROL XL (metoprolol), BREVIBLOC (esmolol HCl), LOTENSIN (benazepril),
COREG (carvedilol), COLAZAL (balsalazide), ELOXATIN (oxaliplatin),
CELEBREX (celecoxib), and SUPRANE (desflurane). The Pediatric Advisory
Committee will also hear an update on TRILEPTAL (oxcarbazepine) and the
FDA Amendments Act of 2007.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/ohrms/dockets/ac/acmenu.htm, click on
the year 2008 and scroll down to the appropriate advisory committee
link.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated: February 26, 2008.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E8-4156 Filed 3-4-08; 8:45 am]
BILLING CODE 4160-01-S
